UH3CA265791

The 10,000 Families Cohort: A New Study to Understand the Environmental Causes of Cancer - Abstract

The 10,000 Families Study (10KFS) will be a new, family-based cohort study in Minnesota, the 'Land of 10,000 Lakes'. Due to our high incidence rates of hematologic malignancy (leukemia, lymphoma, and myelodysplastic syndromes), we will focus our proposal on environmental exposures of concern that are possible hematologic carcinogens with limited evidence in humans as defined by the International Agency for Research on Cancer (IARC).

This includes glyphosate, poly- and perfluoroalkyl substances (PFAS), and radon, all of which have well-described geographic variation in prevalence in the state of Minnesota.

During the UG3 phase, we will evaluate innovative exposure assessment methodologies and recruit diverse participants into the 10KFS cohort. Exposure assessment will include residential history, ambient measures in air and water at current residence, as well as individual-level exposure assessed with silicone wearable bracelets, serum, hair, and urine.

Participants will be recruited from targeted counties that maximize the exposure distribution to our three carcinogens of interest and include under-represented populations from rural and immigrant communities.

We will measure clonal hematopoiesis of indeterminate potential (CHIP), a precursor to heme malignancy, and perturbations in immunity and epigenetics as our primary cancer-related outcomes in the UH3 phase.

Our target is to recruit 8,750 participants from 4,000 households to participate using recruitment strategies that have been developed and pilot tested.

Our central hypothesis is that PFAS, glyphosate, and radon contribute to increased hematologic malignancy specifically, and cancer incidence broadly, in Minnesota.

Cancer incidence will be determined via annual record linkage with the Minnesota Cancer Reporting System (MCRS) and the Virtual Pooled Registry Cancer Linkage System.

The scientific aims in the UG3 phase will be to: 1) evaluate innovative exposure assessment methods for PFAS and glyphosate that can be easily implemented in a large-scale study and 2) describe the exposure burden in under-represented immigrant populations.

We will complete recruitment of the study population in the UH3 phase where the specific aims are to: 1) determine whether levels of radon, glyphosate, and PFAS are associated with increased prevalence of CHIP and 2) utilize epigenomics to test the hypotheses that radon, glyphosate, and PFAS exposure are associated with immune dysregulation and epigenetic signatures.

Our community engagement will be conducted in partnership with the non-profit research institute Hispanic Advocacy and Community Empowerment through Research (HACER), the Minnesota Freemasons and Order of the Eastern Star, and community educators from the Extension Center for Family Development.

The results of this study will provide needed data to inform whether these agents are hematologic carcinogens. It will address documented disparities in exposure that occur within our state and provide a mechanism for community outreach and education concerning these exposures and any potential cancer link.

Regents Of The University Of Minnesota

TO IDENTIFY CANCER RISKS AND RISK REDUCTION STRATEGIES, TO IDENTIFY FACTORS THAT CAUSE CANCER IN HUMANS, AND TO DISCOVER AND DEVELOP MECHANISMS FOR CANCER PREVENTION AND PREVENTIVE INTERVENTIONS IN HUMANS. RESEARCH PROGRAMS INCLUDE: (1) CHEMICAL, PHYSICAL AND MOLECULAR CARCINOGENESIS, (2) SCREENING, EARLY DETECTION AND RISK ASSESSMENT, INCLUDING BIOMARKER DISCOVERY, DEVELOPMENT AND VALIDATION, (3) EPIDEMIOLOGY, (4) NUTRITION AND BIOACTIVE FOOD COMPONENTS, (5) IMMUNOLOGY AND VACCINES, (6) FIELD STUDIES AND STATISTICS, (7) CANCER CHEMOPREVENTION AND INTERCEPTION, (8) PRE-CLINICAL AND CLINICAL AGENT DEVELOPMENT, (9) ORGAN SITE STUDIES AND CLINICAL TRIALS, (10) HEALTH-RELATED QUALITY OF LIFE AND PATIENT-CENTERED OUTCOMES, AND (11) SUPPORTIVE CARE AND MANAGEMENT OF SYMPTOMS AND TOXICITIES. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM: TO EXPAND AND IMPROVE THE SBIR PROGRAM, TO STIMULATE TECHNICAL INNOVATION, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT FUNDING, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION IN INNOVATION AND ENTREPRENEURSHIP BY WOMEN AND SOCIALLY/ECONOMICALLY DISADVANTAGED PERSONS. SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM: TO STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER THROUGH COOPERATIVE RESEARCH AND DEVELOPMENT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT FUNDING, AND FOSTER PARTICIPATION IN INNOVATION AND ENTREPRENEURSHIP BY WOMEN AND SOCIALLY/ECONOMICALLY DISADVANTAGED PERSONS.

93.393 - Cancer Cause and Prevention Research

National Cancer Institute (NCI) [HHS - NIH]

Minneapolis, Minnesota 554550341 United States

Single Zip Code

New Cohorts for Environmental Exposures and Cancer Risk (CEECR; UG3/UH3 Clinical Trial Not Allowed) (RFA-CA-20-049)

Amendment Since initial award the End Date has been extended from 08/31/27 to 08/31/28 and the total obligations have increased 254% from $1,928,905 to $6,827,635.